Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 25 to 36 of 16586 entries
Sorted by: Best Match Show Resources per page
Role of stem cell growth factor/c-Kit in the pathogenesis of irritable bowel syndrome.

Experimental and therapeutic medicine

Chai Y, Huang Y, Tang H, Tu X, He J, Wang T, Zhang Q, Xiong F, Li D, Qiu Z.
PMID: 28413456
Exp Ther Med. 2017 Apr;13(4):1187-1193. doi: 10.3892/etm.2017.4133. Epub 2017 Feb 20.

Irritable bowel syndrome (IBS) is a functional bowel disease with a complicated etiopathogenesis, often characterized by gastrointestinal motility disorder and high visceral sensitivity. IBS is a comprehensive multi-systemic disorder, with the interaction of multiple factors, such as mental stress,...

Cite
Chai Y, Huang Y, Tang H, et al. Role of stem cell growth factor/c-Kit in the pathogenesis of irritable bowel syndrome. Exp Ther Med. 2017;13(4):1187-1193doi: 10.3892/etm.2017.4133.
Chai, Y., Huang, Y., Tang, H., Tu, X., He, J., Wang, T., Zhang, Q., Xiong, F., Li, D., & Qiu, Z. (2017). Role of stem cell growth factor/c-Kit in the pathogenesis of irritable bowel syndrome. Experimental and therapeutic medicine, 13(4), 1187-1193. https://doi.org/10.3892/etm.2017.4133
Chai, Yuna, et al. "Role of stem cell growth factor/c-Kit in the pathogenesis of irritable bowel syndrome." Experimental and therapeutic medicine vol. 13,4 (2017): 1187-1193. doi: https://doi.org/10.3892/etm.2017.4133
Chai Y, Huang Y, Tang H, Tu X, He J, Wang T, Zhang Q, Xiong F, Li D, Qiu Z. Role of stem cell growth factor/c-Kit in the pathogenesis of irritable bowel syndrome. Exp Ther Med. 2017 Apr;13(4):1187-1193. doi: 10.3892/etm.2017.4133. Epub 2017 Feb 20. PMID: 28413456; PMCID: PMC5377426.
Copy Download .nbib Format: NLM
BTK mutations selectively regulate BTK expression and upregulate monocyte XBP1 mRNA in XLA patients.

Immunity, inflammation and disease

Teocchi MA, Domingues Ramalho V, Abramczuk BM, D'Souza-Li L, Santos Vilela MM.
PMID: 26417435
Immun Inflamm Dis. 2015 Sep;3(3):171-81. doi: 10.1002/iid3.57. Epub 2015 Jun 04.

Mutations in the Bruton agammaglobulinemia tyrosine kinase (BTK) gene are responsible for X-linked agammaglobulinemia (XLA). Unfolded or misfolded proteins can trigger stress pathways in the endoplasmic reticulum (ER), known as unfolded protein response (UPR). The aim was to clarify...

Cite
Teocchi MA, Domingues Ramalho V, Abramczuk BM, et al. BTK mutations selectively regulate BTK expression and upregulate monocyte XBP1 mRNA in XLA patients. Immun Inflamm Dis. 2015;3(3):171-81doi: 10.1002/iid3.57.
Teocchi, M. A., Domingues Ramalho, V., Abramczuk, B. M., D'Souza-Li, L., & Santos Vilela, M. M. (2015). BTK mutations selectively regulate BTK expression and upregulate monocyte XBP1 mRNA in XLA patients. Immunity, inflammation and disease, 3(3), 171-81. https://doi.org/10.1002/iid3.57
Teocchi, Marcelo A, et al. "BTK mutations selectively regulate BTK expression and upregulate monocyte XBP1 mRNA in XLA patients." Immunity, inflammation and disease vol. 3,3 (2015): 171-81. doi: https://doi.org/10.1002/iid3.57
Teocchi MA, Domingues Ramalho V, Abramczuk BM, D'Souza-Li L, Santos Vilela MM. BTK mutations selectively regulate BTK expression and upregulate monocyte XBP1 mRNA in XLA patients. Immun Inflamm Dis. 2015 Sep;3(3):171-81. doi: 10.1002/iid3.57. Epub 2015 Jun 04. PMID: 26417435; PMCID: PMC4578518.
Copy Download .nbib Format: NLM
Novel Function of Sprouty4 as a Regulator of Stemness and Differentiation of Embryonic Stem Cells.

Development & reproduction

Lee JY, Park S, Kim KS, Ko JJ, Lee S, Kim KP, Park KS.
PMID: 27660833
Dev Reprod. 2016 Jun;20(2):171-7. doi: 10.12717/DR.2016.20.2.171.

Sprouty (Spry) genes encode inhibitors of the receptor tyrosine kinase signaling cascade, which plays important roles in stem cells. However, the role of Spry4 in the stemness of embryonic stem cells has not been fully elucidated. Here, we used...

Cite
Lee JY, Park S, Kim KS, et al. Novel Function of Sprouty4 as a Regulator of Stemness and Differentiation of Embryonic Stem Cells. Dev Reprod. 2016;20(2):171-7doi: 10.12717/DR.2016.20.2.171.
Lee, J. Y., Park, S., Kim, K. S., Ko, J. J., Lee, S., Kim, K. P., & Park, K. S. (2016). Novel Function of Sprouty4 as a Regulator of Stemness and Differentiation of Embryonic Stem Cells. Development & reproduction, 20(2), 171-7. https://doi.org/10.12717/DR.2016.20.2.171
Lee, Jae-Young, et al. "Novel Function of Sprouty4 as a Regulator of Stemness and Differentiation of Embryonic Stem Cells." Development & reproduction vol. 20,2 (2016): 171-7. doi: https://doi.org/10.12717/DR.2016.20.2.171
Lee JY, Park S, Kim KS, Ko JJ, Lee S, Kim KP, Park KS. Novel Function of Sprouty4 as a Regulator of Stemness and Differentiation of Embryonic Stem Cells. Dev Reprod. 2016 Jun;20(2):171-7. doi: 10.12717/DR.2016.20.2.171. PMID: 27660833; PMCID: PMC5027223.
Copy Download .nbib Format: NLM
DUOX1 silencing in lung cancer promotes EMT, cancer stem cell characteristics and invasive properties.

Oncogenesis

Little AC, Sham D, Hristova M, Danyal K, Heppner DE, Bauer RA, Sipsey LM, Habibovic A, van der Vliet A.
PMID: 27694834
Oncogenesis. 2016 Oct 03;5(10):e261. doi: 10.1038/oncsis.2016.61.

Dual oxidase 1 (DUOX1) is an oxidant-generating enzyme within the airway epithelium that participates in innate airway host defense and epithelial homeostasis. Recent studies indicate that DUOX1 is suppressed in lung cancers by epigenetic silencing, although the importance of...

Cite
Little AC, Sham D, Hristova M, et al. DUOX1 silencing in lung cancer promotes EMT, cancer stem cell characteristics and invasive properties. Oncogenesis. 2016;5(10):e261doi: 10.1038/oncsis.2016.61.
Little, A. C., Sham, D., Hristova, M., Danyal, K., Heppner, D. E., Bauer, R. A., Sipsey, L. M., Habibovic, A., & van der Vliet, A. (2016). DUOX1 silencing in lung cancer promotes EMT, cancer stem cell characteristics and invasive properties. Oncogenesis, 5(10), e261. https://doi.org/10.1038/oncsis.2016.61
Little, A C, et al. "DUOX1 silencing in lung cancer promotes EMT, cancer stem cell characteristics and invasive properties." Oncogenesis vol. 5,10 (2016): e261. doi: https://doi.org/10.1038/oncsis.2016.61
Little AC, Sham D, Hristova M, Danyal K, Heppner DE, Bauer RA, Sipsey LM, Habibovic A, van der Vliet A. DUOX1 silencing in lung cancer promotes EMT, cancer stem cell characteristics and invasive properties. Oncogenesis. 2016 Oct 03;5(10):e261. doi: 10.1038/oncsis.2016.61. PMID: 27694834; PMCID: PMC5117847.
Copy Download .nbib Format: NLM
Afatinib for the first-line treatment of patients with metastatic EGFR-positive NSCLC: a look at the data.

Expert review of clinical pharmacology

Passaro A, Pochesci A, Spitaleri G, Catania C, Noberasco C, Del Signore E, de Marinis F.
PMID: 27626838
Expert Rev Clin Pharmacol. 2016 Oct;9(10):1283-1288. doi: 10.1080/17512433.2016.1233059. Epub 2016 Sep 20.

INTRODUCTION: Epidermal growth factor receptor (EGFR) mutations are detected in about 10-15% of Caucasian and 30-40% of Asian patients with advanced or metastatic non-small-cell lung cancer (NSCLC). In patients harbouring EGFR mutations, the treatment with different available EGFR tyrosine...

Cite
Passaro A, Pochesci A, Spitaleri G, et al. Afatinib for the first-line treatment of patients with metastatic EGFR-positive NSCLC: a look at the data. Expert Rev Clin Pharmacol. 2016;9(10):1283-1288doi: 10.1080/17512433.2016.1233059.
Passaro, A., Pochesci, A., Spitaleri, G., Catania, C., Noberasco, C., Del Signore, E., & de Marinis, F. (2016). Afatinib for the first-line treatment of patients with metastatic EGFR-positive NSCLC: a look at the data. Expert review of clinical pharmacology, 9(10), 1283-1288. https://doi.org/10.1080/17512433.2016.1233059
Passaro, Antonio, et al. "Afatinib for the first-line treatment of patients with metastatic EGFR-positive NSCLC: a look at the data." Expert review of clinical pharmacology vol. 9,10 (2016): 1283-1288. doi: https://doi.org/10.1080/17512433.2016.1233059
Passaro A, Pochesci A, Spitaleri G, Catania C, Noberasco C, Del Signore E, de Marinis F. Afatinib for the first-line treatment of patients with metastatic EGFR-positive NSCLC: a look at the data. Expert Rev Clin Pharmacol. 2016 Oct;9(10):1283-1288. doi: 10.1080/17512433.2016.1233059. Epub 2016 Sep 20. PMID: 27626838.
Copy Download .nbib Format: NLM
Role of Angiopoietins and Tie-2 in Diabetic Retinopathy.

Electronic physician

Khalaf N, Helmy H, Labib H, Fahmy I, El Hamid MA, Moemen L.
PMID: 28979738
Electron Physician. 2017 Aug 25;9(8):5031-5035. doi: 10.19082/5031. eCollection 2017 Aug.

OBJECTIVE: The aim of this study was to determine the serum levels of angiopoietin-1 (Ang-1), angiopoietin-2 (Ang-2), soluble vascular endothelial tyrosine kinase receptor (Tie-2) and vascular endothelial growth factor (VEGF), in the serum of type 2 diabetic patients having...

Cite
Khalaf N, Helmy H, Labib H, et al. Role of Angiopoietins and Tie-2 in Diabetic Retinopathy. Electron Physician. 2017;9(8):5031-5035doi: 10.19082/5031.
Khalaf, N., Helmy, H., Labib, H., Fahmy, I., El Hamid, M. A., & Moemen, L. (2017). Role of Angiopoietins and Tie-2 in Diabetic Retinopathy. Electronic physician, 9(8), 5031-5035. https://doi.org/10.19082/5031
Khalaf, Nervana, et al. "Role of Angiopoietins and Tie-2 in Diabetic Retinopathy." Electronic physician vol. 9,8 (2017): 5031-5035. doi: https://doi.org/10.19082/5031
Khalaf N, Helmy H, Labib H, Fahmy I, El Hamid MA, Moemen L. Role of Angiopoietins and Tie-2 in Diabetic Retinopathy. Electron Physician. 2017 Aug 25;9(8):5031-5035. doi: 10.19082/5031. eCollection 2017 Aug. PMID: 28979738; PMCID: PMC5614288.
Copy Download .nbib Format: NLM
Purification and characterization of an extracellular β-xylosidase from Pseudozyma hubeiensis NCIM 3574 (PhXyl), an unexplored yeast.

AMB Express

Mhetras N, Liddell S, Gokhale D.
PMID: 27637943
AMB Express. 2016 Dec;6(1):73. doi: 10.1186/s13568-016-0243-7. Epub 2016 Sep 15.

This paper reports on the production of β-xylosidase from an unexplored yeast, Pseudozyma hubeinsis. The expression of this enzyme could be induced by beech wood xylan when the yeast was grown at 27 °C. The enzyme was purified to...

Cite
Mhetras N, Liddell S, Gokhale D. Purification and characterization of an extracellular β-xylosidase from Pseudozyma hubeiensis NCIM 3574 (PhXyl), an unexplored yeast. AMB Express. 2016;6(1):73doi: 10.1186/s13568-016-0243-7.
Mhetras, N., Liddell, S., & Gokhale, D. (2016). Purification and characterization of an extracellular β-xylosidase from Pseudozyma hubeiensis NCIM 3574 (PhXyl), an unexplored yeast. AMB Express, 6(1), 73. https://doi.org/10.1186/s13568-016-0243-7
Mhetras, Nutan, et al. "Purification and characterization of an extracellular β-xylosidase from Pseudozyma hubeiensis NCIM 3574 (PhXyl), an unexplored yeast." AMB Express vol. 6,1 (2016): 73. doi: https://doi.org/10.1186/s13568-016-0243-7
Mhetras N, Liddell S, Gokhale D. Purification and characterization of an extracellular β-xylosidase from Pseudozyma hubeiensis NCIM 3574 (PhXyl), an unexplored yeast. AMB Express. 2016 Dec;6(1):73. doi: 10.1186/s13568-016-0243-7. Epub 2016 Sep 15. PMID: 27637943; PMCID: PMC5023640.
Copy Download .nbib Format: NLM
Circulating microRNAs in patients with hormone receptor-positive, metastatic breast cancer treated with dovitinib.

Clinical and translational medicine

Shivapurkar N, Vietsch EE, Carney E, Isaacs C, Wellstein A.
PMID: 28980224
Clin Transl Med. 2017 Oct 04;6(1):37. doi: 10.1186/s40169-017-0169-y.

BACKGROUND: Serial analysis of biomarkers in the circulation of patients undergoing treatment ("liquid biopsies") can provide new insights into drug effects. In particular the analysis of cell-free, circulating nucleic acids such as microRNAs (miRs) can reveal altered expression patterns...

Cite
Shivapurkar N, Vietsch EE, Carney E, et al. Circulating microRNAs in patients with hormone receptor-positive, metastatic breast cancer treated with dovitinib. Clin Transl Med. 2017;6(1):37doi: 10.1186/s40169-017-0169-y.
Shivapurkar, N., Vietsch, E. E., Carney, E., Isaacs, C., & Wellstein, A. (2017). Circulating microRNAs in patients with hormone receptor-positive, metastatic breast cancer treated with dovitinib. Clinical and translational medicine, 6(1), 37. https://doi.org/10.1186/s40169-017-0169-y
Shivapurkar, Narayan, et al. "Circulating microRNAs in patients with hormone receptor-positive, metastatic breast cancer treated with dovitinib." Clinical and translational medicine vol. 6,1 (2017): 37. doi: https://doi.org/10.1186/s40169-017-0169-y
Shivapurkar N, Vietsch EE, Carney E, Isaacs C, Wellstein A. Circulating microRNAs in patients with hormone receptor-positive, metastatic breast cancer treated with dovitinib. Clin Transl Med. 2017 Oct 04;6(1):37. doi: 10.1186/s40169-017-0169-y. PMID: 28980224; PMCID: PMC5628092.
Copy Download .nbib Format: NLM
Ceramide synthesis regulates T cell activity and GVHD development.

JCI insight

Sofi MH, Heinrichs J, Dany M, Nguyen H, Dai M, Bastian D, Schutt S, Wu Y, Daenthanasanmak A, Gencer S, Zivkovic A, Szulc Z, Stark H, Liu C, Chang YJ, Ogretmen B, Yu XZ.
PMID: 28515365
JCI Insight. 2017 May 18;2(10). doi: 10.1172/jci.insight.91701. eCollection 2017 May 18.

Allogeneic hematopoietic cell transplantation (allo-HCT) is an effective immunotherapy for a variety of hematologic malignances, yet its efficacy is impeded by the development of graft-versus-host disease (GVHD). GVHD is characterized by activation, expansion, cytokine production, and migration of alloreactive...

Cite
Sofi MH, Heinrichs J, Dany M, et al. Ceramide synthesis regulates T cell activity and GVHD development. JCI Insight. 2017;2(10)doi: 10.1172/jci.insight.91701.
Sofi, M. H., Heinrichs, J., Dany, M., Nguyen, H., Dai, M., Bastian, D., Schutt, S., Wu, Y., Daenthanasanmak, A., Gencer, S., Zivkovic, A., Szulc, Z., Stark, H., Liu, C., Chang, Y. J., Ogretmen, B., & Yu, X. Z. (2017). Ceramide synthesis regulates T cell activity and GVHD development. JCI insight, 2(10), . https://doi.org/10.1172/jci.insight.91701
Sofi, M Hanief, et al. "Ceramide synthesis regulates T cell activity and GVHD development." JCI insight vol. 2,10 (2017). doi: https://doi.org/10.1172/jci.insight.91701
Sofi MH, Heinrichs J, Dany M, Nguyen H, Dai M, Bastian D, Schutt S, Wu Y, Daenthanasanmak A, Gencer S, Zivkovic A, Szulc Z, Stark H, Liu C, Chang YJ, Ogretmen B, Yu XZ. Ceramide synthesis regulates T cell activity and GVHD development. JCI Insight. 2017 May 18;2(10). doi: 10.1172/jci.insight.91701. eCollection 2017 May 18. PMID: 28515365; PMCID: PMC5436544.
Copy Download .nbib Format: NLM
Pharmacokinetics and pharmacodynamics of subcutaneously administered PYY3-36 and its analogues in vivo.

Lancet (London, England)

Cegla J, Cuenco J, Minnion J, Ghourab S, Hostomska K, Tan T, Bloom S.
PMID: 26312850
Lancet. 2015 Feb 26;385:S28. doi: 10.1016/S0140-6736(15)60343-9.

BACKGROUND: Obesity is an emergent epidemic associated with morbidity, mortality, and psychosocial effects. One of the key gut hormones that controls appetite is peptide tyrosine-tyrosine 3-36 (PYY3-36) whose circulating half-life is only 8 min. A long-acting analogue of PYY3-36...

Cite
Cegla J, Cuenco J, Minnion J, et al. Pharmacokinetics and pharmacodynamics of subcutaneously administered PYY3-36 and its analogues in vivo. Lancet. 2015;385:S28doi: 10.1016/S0140-6736(15)60343-9.
Cegla, J., Cuenco, J., Minnion, J., Ghourab, S., Hostomska, K., Tan, T., & Bloom, S. (2015). Pharmacokinetics and pharmacodynamics of subcutaneously administered PYY3-36 and its analogues in vivo. Lancet (London, England), 385S28. https://doi.org/10.1016/S0140-6736(15)60343-9
Cegla, Jaimini, et al. "Pharmacokinetics and pharmacodynamics of subcutaneously administered PYY3-36 and its analogues in vivo." Lancet (London, England) vol. 385 (2015): S28. doi: https://doi.org/10.1016/S0140-6736(15)60343-9
Cegla J, Cuenco J, Minnion J, Ghourab S, Hostomska K, Tan T, Bloom S. Pharmacokinetics and pharmacodynamics of subcutaneously administered PYY3-36 and its analogues in vivo. Lancet. 2015 Feb 26;385:S28. doi: 10.1016/S0140-6736(15)60343-9. PMID: 26312850.
Copy Download .nbib Format: NLM
Development of Asymmetric Facial Depigmentation in a Patient Treated with Dasatinib with New-Onset Hypovitaminosis D: Case Report and Review of the Literature.

Case reports in dermatological medicine

Webb KC, Harasimowicz M, Janeczek M, Speiser J, Swan J, Tung R.
PMID: 28424749
Case Rep Dermatol Med. 2017;2017:9359086. doi: 10.1155/2017/9359086. Epub 2017 Mar 23.

Dasatinib is a second-generation tyrosine kinase inhibitor (TKI) used to treat imatinib-resistant chronic myelogenous leukemia (CML), as well as other Philadelphia chromosome-positive lymphoproliferative disorders. While the most commonly reported cutaneous side effects with this therapy include a morbilliform eruption,...

Cite
Webb KC, Harasimowicz M, Janeczek M, et al. Development of Asymmetric Facial Depigmentation in a Patient Treated with Dasatinib with New-Onset Hypovitaminosis D: Case Report and Review of the Literature. Case Rep Dermatol Med. 2017;2017:9359086doi: 10.1155/2017/9359086.
Webb, K. C., Harasimowicz, M., Janeczek, M., Speiser, J., Swan, J., & Tung, R. (2017). Development of Asymmetric Facial Depigmentation in a Patient Treated with Dasatinib with New-Onset Hypovitaminosis D: Case Report and Review of the Literature. Case reports in dermatological medicine, 20179359086. https://doi.org/10.1155/2017/9359086
Webb, Kirsten C, et al. "Development of Asymmetric Facial Depigmentation in a Patient Treated with Dasatinib with New-Onset Hypovitaminosis D: Case Report and Review of the Literature." Case reports in dermatological medicine vol. 2017 (2017): 9359086. doi: https://doi.org/10.1155/2017/9359086
Webb KC, Harasimowicz M, Janeczek M, Speiser J, Swan J, Tung R. Development of Asymmetric Facial Depigmentation in a Patient Treated with Dasatinib with New-Onset Hypovitaminosis D: Case Report and Review of the Literature. Case Rep Dermatol Med. 2017;2017:9359086. doi: 10.1155/2017/9359086. Epub 2017 Mar 23. PMID: 28424749; PMCID: PMC5382301.
Copy Download .nbib Format: NLM
Structural basis of Tie2 activation and Tie2/Tie1 heterodimerization.

Proceedings of the National Academy of Sciences of the United States of America

Leppänen VM, Saharinen P, Alitalo K.
PMID: 28396439
Proc Natl Acad Sci U S A. 2017 Apr 25;114(17):4376-4381. doi: 10.1073/pnas.1616166114. Epub 2017 Apr 10.

The endothelial cell (EC)-specific receptor tyrosine kinases Tie1 and Tie2 are necessary for the remodeling and maturation of blood and lymphatic vessels. Angiopoietin-1 (Ang1) growth factor is a Tie2 agonist, whereas Ang2 functions as a context-dependent agonist/antagonist. The orphan...

Cite
Leppänen VM, Saharinen P, Alitalo K. Structural basis of Tie2 activation and Tie2/Tie1 heterodimerization. Proc Natl Acad Sci U S A. 2017;114(17):4376-4381doi: 10.1073/pnas.1616166114.
Leppänen, V. M., Saharinen, P., & Alitalo, K. (2017). Structural basis of Tie2 activation and Tie2/Tie1 heterodimerization. Proceedings of the National Academy of Sciences of the United States of America, 114(17), 4376-4381. https://doi.org/10.1073/pnas.1616166114
Leppänen, Veli-Matti, et al. "Structural basis of Tie2 activation and Tie2/Tie1 heterodimerization." Proceedings of the National Academy of Sciences of the United States of America vol. 114,17 (2017): 4376-4381. doi: https://doi.org/10.1073/pnas.1616166114
Leppänen VM, Saharinen P, Alitalo K. Structural basis of Tie2 activation and Tie2/Tie1 heterodimerization. Proc Natl Acad Sci U S A. 2017 Apr 25;114(17):4376-4381. doi: 10.1073/pnas.1616166114. Epub 2017 Apr 10. PMID: 28396439; PMCID: PMC5410806.
Copy Download .nbib Format: NLM
Showing 25 to 36 of 16586 entries